Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

662P - Pembrolizumab (pembro) monotherapy as first-line therapy in advanced non–clear cell renal cell carcinoma (nccRCC): Results after a minimum of 34 months of follow-up from KEYNOTE-427 cohort B

Date

16 Sep 2021

Session

ePoster Display

Topics

Tumour Site

Renal Cell Cancer

Presenters

Jae-Lyun Lee

Citation

Annals of Oncology (2021) 32 (suppl_5): S678-S724. 10.1016/annonc/annonc675

Authors

J. Lee1, D.F. McDermott2, M. Ziobro3, C. Suarez4, P. Langiewicz5, V.B. Matveev6, P. Wiechno7, R. Gafanov8, P. Tomczak9, F. Pouliot10, F. Donskov11, B.Y. Alekseev12, S.J. Shin13, G.A. Bjarnason14, D. Castellano15, H. Liu16, J. Burgents16, K. Rodriguez-Lopez16, M.B. Atkins17

Author affiliations

  • 1 Oncology Department, Asan Medical Center - University of Ulsan College of Medicine, 138-931 - Seoul/KR
  • 2 Hematology/oncology, Beth Israel Deaconess Medical Center, 2215 - Boston/US
  • 3 Medical Oncology, Centrum Onkologii-Instytut im. Marii Sklodowskiej, Kraków/PL
  • 4 Oncology, Vall d´Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d´Hebron, Vall d´Hebron Barcelona Hospital Campus, Barcelona/ES
  • 5 Medical Oncology, Wojskowy Instytut Medyczny Centralny Szpital Medyczny MON, 04-141 - Warsaw/PL
  • 6 Medical Oncology, N.N. Blokhin National Medical Research Center of Oncology, 115478 - Moscow/RU
  • 7 Medical Oncology, Narodowy Instytut Onkologii-Państwowy Instytut Badawczy im. Marii Skłodowskiej-Curie, 02-781 - Warsaw/PL
  • 8 Medical Oncology, Russian Scientific Center of Roentgenoradiology, 117997 - Moscow/RU
  • 9 Medical Oncology, Clinical Hospital No. 1 of the Poznan University of Medical Sciences, 61-878 - Poznan/PL
  • 10 Surgery Department, Universite Laval, CHU de Quebec, G1R 3S1 - Quebec City/CA
  • 11 Department Of Oncology, Aarhus University Hospital, 8000 - Aarhus/DK
  • 12 Medical Oncology, P.A. Hertsen Moscow Oncology Research Institute, 125284 - Moscow/RU
  • 13 Medical Oncology, Yonsei University College of Medicine, 120-752 - Seoul/KR
  • 14 Medical Oncology, Sunnybrook Odette Cancer Centre, Toronto/CA
  • 15 Medical Oncology Department, Hospital Universitario 12 de Octubre, I +12 Research Institute, 28041 - Madrid/ES
  • 16 Medical Oncology, Merck & Co., Inc., 07033 - Kenilworth/US
  • 17 Department Of Medical Oncology, Georgetown-Lombardi Comprehensive Cancer Center, 20007 - Washington/US

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 662P

Background

In the single-arm, open-label, phase II KEYNOTE-427 study, first-line pembro monotherapy showed antitumor activity in nccRCC (cohort B) (NCT02853344). We present updated efficacy and safety results after a minimum of 34.1 mo of follow-up for pts with nccRCC.

Methods

Pts with histologically confirmed nccRCC and measurable disease per RECIST v1.1 who had not previously received systemic therapy were given pembro 200 mg IV every 3 weeks for up to 35 doses or until progressive disease, unacceptable toxicity, or withdrawal of consent. Primary end point was ORR per RECIST v.1.1 by blinded independent central review (BICR). Secondary end points were DOR and PFS per RECIST v1.1 by BICR, OS, and safety.

Results

Of 165 pts, 118 (71.5%) had papillary histology, 21 (12.7%) had chromophobe histology, and 26 (15.8%) were unclassified. As of February 5, 2021, median duration of therapy was 6.9 mo (range, 0.03-29.2); 55 (33.3%) pts received ≥12 mo of treatment and 25 (15.2%) completed pembro treatment (35 doses). Median time from enrollment to data cutoff date was 42.9 mo (range, 34.1-50.2). ORR was 26.7% (95% CI, 20.1-34.1; 11 CRs, 33 PRs). Median DOR was 29.0 mo (95% CI, 9.8-not reached); an estimated 53.8% of responders remained in response for at least 24 mo. Median PFS was 4.2 mo (95% CI, 2.9-5.6) and median OS was 29.9 mo (95% CI, 24.3-37.4). At 30 mo, the PFS rate was 16.9% and the OS rate was 48.4%. Most pts (59.4%) had a reduction in the sum of target lesions; 16.4% had a ≥80% reduction in the sum of target lesions. ORR (95% CI) was 28.8% (95% CI, 20.8-37.9), 9.5% (95% CI, 1.2-30.4), and 30.8% (95% CI, 14.3-51.8) for pts with papillary, chromophobe, and unclassified histology, respectively. Treatment-related AEs occurred in 114 (69.1%) of pts and grade 3-5 treatment-related AEs occurred in 28 (17.0%) pts. Two pts died of treatment-related AEs (pneumonia and cardiac arrest).

Conclusions

After a minimum of 34.1 mo of follow-up, pembro monotherapy continued to demonstrate promising antitumor activity as first-line treatment in advanced nccRCC. No new safety signals were observed.

Clinical trial identification

NCT02853344, August 2, 2016.

Editorial acknowledgement

Medical writing and/or editorial assistance was provided by Matthew Grzywacz, PhD of ApotheCom (Yardley, PA, USA). This assistance was funded by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.

Legal entity responsible for the study

Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.

Funding

Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.

Disclosure

J. Lee: Financial Interests, Personal, Other, Honoraria: Novartis Korea, AstraZeneca; Financial Interests, Personal, Advisory Role, Advisory/Consultancy: Pfizer Korea, Ipsen Korea, Sanofi Aventis, Astella Korea, BMS, MSD, Merck, Esai, AstraZeneca; Financial Interests, Personal, Stocks/Shares: Merck, Amgen, Johnson and Johnson, Myovant Science; Financial Interests, Institutional, Research Grant: Pfizer, Ipsen, BMS, MSD, Merck, Esai, Roche, AstraZeneca, Exelixis, Seagen. D.F. McDermott: Financial Interests, Personal, Other, Honoraria: BMS, Pfizer, Merck, Alkermes, Inc., EMD, Serono, Eli Lilly and Company, Iovance, Eisai Inc. Werewolf Therapeutics, Calithera Biosciences; Financial Interests, Personal, Research Grant: BMS, Merck, Genentech, Pfizer, Exelixis, X4 Pharma, Alkermes, Inc., Checkmate Pharmaceuticals. M. Ziobro: Financial Interests, Personal, Other, Honoraria: BMS, MSD, Novartis, Pfizer, Roche; Financial Interests, Personal, Advisory Role, Advisory/Consultancy: BMS, MSD, Pierre-Fabre; Financial Interests, Personal, Speaker’s Bureau, Speaker Bureau/Expert Testimony: BMS, MSD; Financial Interests, Personal, Other, Travel expenses, including accommodations: BMS, MSD, Novartis, Pfizer, Roche. C. Suarez: Financial Interests, Personal, Advisory Role: Bristol-Myers Squibb, Ipsen, Sanofi, Pfizer, EUSA Pharma, Astellas Pharma, Novartis, Merck Sharp & Dohme Speakers’ Bureau: Bristol-Myers Squibb, Ipsen, PfizerRoche/Genentech, AstraZeneca, Merck Sharp & Dohme; Financial Interests, Institutional, Research Grant: Astellas Pharma, Roche/Genentech, Exelixis, AstraZeneca, Bristol-Myers Squibb, Pfizer, Novartis, Janssen Oncology, Calithera Biosciences, AB Science, Arog, AVEO, Bayer, SFJ Pharmaceuticals Group, Blueprint Medicines, Clovis Oncology, Boehringer Ingelheim,; Financial Interests, Personal, Other, Travel Expenses: Bristol-Myers Squibb, Roche, Ipsen. P. Langiewicz: Financial Interests, Personal, Research Grant: Merck, Astellas. V.B. Matveev: Financial Interests, Personal, Other, Honoraria: Bayer, Janssen, AstraZeneca, Astellas, BMS, Merk, Roche; Financial Interests, Personal, Advisory Role: Eisai. P. Wiechno: Financial Interests, Personal, Invited Speaker, Honoraria: Pfitzer, Astellas, Janssen Cilag, Bayer, MSD, BMS; Financial Interests, Personal, Advisory Role, Advisory/Consultancy: Pfitzer, Astellas, Janssen Cilag, Bayer, MSD, BMS. R. Gafanov: Financial Interests, Institutional, Other, Honoraria: Janssen, MSD, Bayer, AstraZeneca; Financial Interests, Personal, Advisory Role, Advisory/Consultancy: Astellas, Janssen,Sanofi, Pfizer, BMS, MSD, Bayer, Eisai, Ipsen, Pierre Fabre, AstraZeneca; Financial Interests, Personal, Speaker’s Bureau, Speaker Bureau/Expert Testimony: Astellas, Janssen,Sanofi, Pfizer, BMS, MSD, Bayer, Eisai, Ipsen, Pierre Fabre, AstraZeneca; Financial Interests, Personal, Leadership Role: Astellas, Janssen,Sanofi, Pfizer, BMS, MSD, Bayer, Eisai, Ipsen, Pierre Fabre, AstraZeneca; Financial Interests, Institutional, Research Grant: Janssen,MSD, Bayer, AstraZeneca. F. Pouliot: Financial Interests, Personal, Other, Honoraria: Tersera, Janssen, Astellas, Bayer, Sanofi, Ferring; Financial Interests, Personal, Advisory Role, Advisory/Consultancy: Tersera, Janssen, Astellas, Bayer, Sanofi, Ferring, Merck; Financial Interests, Personal, Speaker’s Bureau, Speaker Bureau/Expert Testimony: Janssen; Financial Interests, Personal, Other, Travel expenses, including accommodations: Amgen; Financial Interests, Institutional, Research Grant: Astellas, Bayer. F. Donskov: Financial Interests, Personal, Research Grant: Ipsen, Pfizer, MSD. B.Y. Alekseev: Financial Interests, Personal, Other, Honoraria: Astellas, AstraZeneca, Bayer, BMS, Eisai, Ferring, Ipsen, Janssen, Merck, MSD, Pfizer, Roche, Sanofi; Financial Interests, Institutional, Other, Honoraria: Astellas, AstraZeneca, Bayer, BMS, Eisai, Ferring, Ipsen, Janssen, Merck, MSD, Pfizer, Roche; Financial Interests, Personal, Advisory Role: Astellas, AstraZeneca, Bayer, BMS, Eisai, Ipsen, Janssen, Merck, MSD, Pfizer, Roche; Financial Interests, Personal, Speaker’s Bureau: Astellas, AstraZeneca, Bayer, BMS, Eisai, Ferring, Ipsen, Janssen, Merck, MSD, Pfizer, Roche, Sanofi; Financial Interests, Personal, Funding: Astellas, AstraZeneca, Bayer, BMS, Eisai, Ferring, Ipsen, Janssen, Merck, MSD, Pfizer, Roche, Sanofi; Financial Interests, Personal, Other, Travel Expenses: Astellas, AstraZeneca, Bayer, BMS, Eisai, Ferring, Ipsen, Janssen, Merck, MSD, Pfizer, Roche; Financial Interests, Institutional, Research Grant: Astellas, AstraZeneca, Bayer, BMS, Eisai, Ferring, Ipsen, Janssen, Merck, MSD, Pfizer, Roche. G.A. Bjarnason: Financial Interests, Personal, Other, Honoraria: Pfizer, BMS, Eisai, Ipsen, Merck; Financial Interests, Personal, Advisory Role: Pfizer, BMS, Eisai, Ipsen, Merck; Financial Interests, Personal, Research Grant: Pfizer. Merck. D. Castellano: Financial Interests, Personal, Advisory Board: Astellas, AstraZeneca, BMS, GSK, Ipsen, Janssen, MSD, Novartis, Pfizer, Roche; Non-Financial Interests, Institutional, Principal Investigator: Astellas, AstraZeneca, Bayer, BMS, Clovis, Eisai, Exelisis, GSK, Ipsen, Janssen, Lilly, MSD, Pfizer, QED Therapeutics, Roche; Non-Financial Interests, Personal, Member, Executive member: SOGUG (Spanish Oncology Genito-Urinary Group). H. Liu: Financial Interests, Personal, Full or part-time Employment: Merck & Co., Inc.; Financial Interests, Personal, Stocks/Shares: Merck & Co., Inc. J. Burgents: Financial Interests, Personal, Full or part-time Employment: Merck & Co., Inc.; Financial Interests, Personal, Stocks/Shares: Merck & Co., Inc. K. Rodriguez-Lopez: Financial Interests, Personal, Full or part-time Employment: Merck & Co., Inc.; Financial Interests, Personal, Stocks/Shares: Merck & Co., Inc. M.B. Atkins: Financial Interests, Personal, Advisory Role, Advisory/consultancy: BMS, Merck, Novartis, Arrowhead, Eisai, Aveo, Pfizer, Werewolf, Fathom, Pneuma, Leads, Pyxis Oncology, PACT, Elpis, X4Pharma, ValoHealth, ScholarRock, Surface, Genentech-Roche, Exelixis, ImmunoCore, Iovance, Idera, Agenus, Apexigen, Asher Bio, Neoleukin; Financial Interests, Personal, Stocks/Shares: Werewolf, Pyxis Oncology, Elpis; Financial Interests, Institutional, Research Grant: BMS, Merck, DOD, NIH, AstraZeneca, Calithera; Financial Interests, Personal, Other, Non-remunerated activity/ies: SITC, MRF, MRA, NIH. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.